Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. (“Progyny” or “the Company”) (NASDAQ: PGNY). Investors who purchased Progyny securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Progyny has violated federal securities laws.
Investigation Details
On September 18, 2024, Progyny disclosed in a filing with the U.S. Securities and Exchange Commission that the Company “was recently notified by a significant client (the ‘Client’) that the Client has elected to exercise a 90-day option to terminate its services agreement with the Company, effective as of January 1, 2025.” On September 19, 2024, JMP Securities downgraded Progyny to Market Perform from Outperform, stating that “the loss of [Progyny’s] largest client causes us to appropriately contemplate the potential for lower retention rates going forward.” On this news, Progyny’s stock price fell sharply during intraday trading on September 19, 2024.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Progyny securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
PGNY — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”